维利西呱的代谢与药代动力学药物相互作用特征:临床前与I期健康志愿者研究结果
维利西呱是 soluble guanylate cyclase 刺激剂,用于恶化性慢性心力衰竭。本研究通过体外实验、人体质量平衡研究和十项I期药物相互作用研究,评估其清除机制与相互作用潜力。结果显示维利西呱主要经 UGT1A9 和 UGT1A1 葡萄糖醛酸化,作为 perpetrator 风险低,作为 victim 的药物相互作用变化幅度不需在III期调整剂量,适合多病共存多药治疗患者。
要点
- 维利西呱主要代谢途径为 UGT1A9 和 UGT1A1 介导的葡萄糖醛酸化。
- 体外和I期研究显示维利西呱作为 perpetrator 的药代动力学相互作用风险低。
- 作为 victim 的药物相互作用变化幅度不需在III期推荐剂量调整。
核心结论
- 维利西呱药代动力学相互作用潜力低,适合多病共存需多药治疗的患者人群。
研究设计与样本
- 体外使用人肝细胞、肝微粒体和重组酶表征生物转化及 perpetrator 特性。
- 人体质量平衡研究评估维利西呱的消除途径。
- 十项健康志愿者I期药物相互作用研究,维利西呱口服与奥美拉唑、镁/铝氢氧化物、酮康唑、利福平、甲芬那酸、咪达唑仑、华法林、地高辛、沙库巴曲/缬沙坦、阿司匹林或西地那非合用。
主要发现
- 人体质量平衡研究中,平均总放射性回收率为给药量的98.3%(尿53.1%,粪45.2%)。
- 维利西呱主要代谢途径为经尿苷二磷酸-葡萄糖醛酸转移酶1A9和1A1的葡萄糖醛酸化。
- 体外研究显示维利西呱通过抑制细胞色素P450、尿苷二磷酸-葡萄糖醛酸转移酶同工酶或主要转运蛋白,或诱导细胞色素P450而作为 perpetrator 的风险低。
- I期药物相互作用研究支持体外观察结果。
- 评估维利西呱作为 victim 药物的I期研究显示变化幅度不需在III期推荐剂量调整。
临床怎么用
- 维利西呱与常见合并用药(如奥美拉唑、酮康唑、利福平、华法林、地高辛、沙库巴曲/缬沙坦、阿司匹林、西地那非等)合用时,基于I期研究结果通常不需因药代动力学相互作用调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because of comorbidities. Hence, understanding the clearance mechanisms, elimination, and potential for pharmacokinetic drug-drug interactions of vericiguat is important for dose recommendations in this patient population. METHODS: Biotransformation and perpetrator properties of vericiguat were characterized in vitro using human hepatocytes, liver microsomes, and recombinant enzymes. This was complemented by a human mass balance study and ten drug-drug interaction studies in healthy volunteers wherein vericiguat was co-administered orally with omeprazole, magnesium/aluminum hydroxide, ketoconazole, rifampicin, mefenamic acid, midazolam, warfarin, digoxin, sacubitril/valsartan, aspirin, or sildenafil. RESULTS: In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively). The main metabolic pathway of vericiguat is glucuronidation via uridine diphosphate-glucuronosyltransferase 1A9 and 1A1. In vitro studies revealed a low risk of vericiguat acting as a perpetrator by inhibiting cytochrome P450s, uridine diphosphate-glucuronosyltransferase isoforms, or major transport proteins, or by inducing cytochrome P450s. These observations were supported by phase I drug-drug interaction studies. Phase I studies that assessed the propensity of vericiguat as a victim drug showed changes in the range that did not warrant recommendations for dose adjustment in phase III. CONCLUSIONS: A low pharmacokinetic interaction potential of vericiguat was estimated from in vitro data and confirmed in vivo. Thus, vericiguat is suitable for a patient population with multiple comorbidities requiring polypharmacy.
引用
- Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. Clin Pharmacokinet. 2020. PMID: 32458378. doi:10.1007/s40262-020-00895-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。